March 22, 2022
Intercept Pharmaceuticals Inc. has defeated a proposed securities class action accusing it of covering up reports of fatalities and injuries caused by a liver disease drug, after a New York federal judge found the shareholders failed to adequately plead scienter, loss causation or any material misrepresentations or omissions.